Anika Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Anika Therapeutics es Cheryl Blanchard , nombrado en Feb 2020, tiene una permanencia de 4.75 años. compensación anual total es $4.46M, compuesta por 16.3% salario y 83.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.2% de las acciones de la empresa, por valor de €2.93M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.2 años, respectivamente.

Información clave

Cheryl Blanchard

Chief Executive Officer (CEO)

US$4.5m

Compensación total

Porcentaje del salario del CEO	16.3%
Permanencia del CEO	4.8yrs
Participación del CEO	1.2%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Cheryl Blanchard en comparación con los beneficios de Anika Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$74m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$4m	US$726k	-US$83m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$6m	US$695k	-US$15m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$4m	US$668k	US$4m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$10m	US$548k	-US$24m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$28m
Dec 31 2019	US$187k	n/a	US$27m
Sep 30 2019	n/a	n/a	US$31m
Jun 30 2019	n/a	n/a	US$29m
Mar 31 2019	n/a	n/a	US$30m
Dec 31 2018	US$167k	n/a	US$19m

Compensación vs. Mercado: La compensación total de Cheryl($USD4.46M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD852.77K).

Compensación vs. Ingresos: La compensación de Cheryl ha sido consistente con los resultados de la empresa en el último año.

CEO

Cheryl Blanchard (60 yo)

4.8yrs

Permanencia

US$4,459,800

Compensación

Dr. Cheryl Renee Blanchard, Ph. D. is Director of Elute, Inc. from May 2013. She serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director o...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Cheryl Blanchard	President	4.8yrs	US$4.46m	1.2% € 2.9m
Anne Nunes	Senior VP & COO	3.2yrs	US$1.01m	0.092% € 225.7k
David Colleran	Executive VP	4.7yrs	US$1.55m	0.23% € 552.5k
Michael Levitz	Executive Officer	less than a year	US$1.65m	0.32% € 786.3k
Stephen Griffin	Executive VP	less than a year	sin datos	sin datos
Ian McLeod	VP & Chief Accounting Officer	no data	sin datos	sin datos
Mark Namaroff	Vice President of Investor Relations	no data	sin datos	sin datos
James Chase	Senior Vice President of International Sales & Marketing	4.5yrs	sin datos	sin datos
Ben Joseph	Vice President of Commercial & Corporate Development	2.8yrs	sin datos	sin datos
Lisa Funiciello	Vice President of Human Resources	2.8yrs	sin datos	sin datos

3.0yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AKP se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Cheryl Blanchard	President	6.3yrs	US$4.46m	1.2% € 2.9m
William Jellison	Independent Director	less than a year	sin datos	0.018% € 45.2k
John Henneman	Independent Chair of the Board	5.3yrs	US$249.81k	0.20% € 501.3k
Susan L. Vogt	Independent Director	6.1yrs	US$248.98k	0.21% € 507.0k
Sheryl Conley	Independent Director	3.1yrs	US$242.48k	0.14% € 333.3k
Glenn Larsen	Independent Director	9.8yrs	US$237.48k	0.21% € 507.8k
Joseph Capper	Independent Director	less than a year	sin datos	sin datos
Gary Fischetti	Independent Director	1.6yrs	US$571.00k	0.089% € 219.5k
Stephen Richard	Independent Director	4.2yrs	US$248.98k	0.19% € 467.8k

4.2yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de AKP se considera experimentada (4.2 años de antigüedad promedio).

Anika Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. Announces Board Changes

Anika Therapeutics, Inc. Announces CFO Changes

President recently bought €189k worth of stock

Independent Director recently sold €71k worth of stock

Independent Director recently sold €107k worth of stock

Recent updates

Now 41% undervalued after recent price drop

Third quarter 2024 earnings released: US$2.03 loss per share (vs US$0.45 loss in 3Q 2023)

Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: US$0.006 loss per share (vs US$0.19 loss in 2Q 2023)

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.71 loss in 1Q 2023)

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$1.02 loss in FY 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.29 loss in 3Q 2022)

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2022)

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.20 loss in 1Q 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$1.02 loss per share (vs US$0.29 profit in FY 2021)

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.039 profit in 3Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings released: US$0.20 loss per share (vs US$0.45 profit in 2Q 2021)

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 profit in 1Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought €189k worth of stock

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Independent Director recently sold €71k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Revenue misses expectations

New 90-day low: €29.20

Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €34.00

Independent Director recently sold €107k worth of stock

New 90-day low: €27.60

Third quarter 2020 earnings released: US$0.45 loss per share

Revenue beats expectations

Anika Therapeutics, Inc. Suspends Financial Guidance for the Full Year 2020

First half earnings released

Anika Therapeutics, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Análisis de compensación del CEO

CEO